[Job Opening] Business Development Manager – San Diego office

Share This Post

Yuhan USA Corporation was established in January 2018 as a wholly-owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 94-year heritage.


As an outpost of Yuhan’s globalization strategy, Yuhan USA is seeking new opportunities to expand its business domain through searching new drug materials and companies that match with Yuhan’s targeted therapeutic areas under its open innovation platform.


Business Development Manager will have the responsibility for exploring the new business opportunities and In-licensing novel assets that align with Yuhan USA’s focused therapeutic areas.

Responsibilities:
– Build relationships with potential business partners, outside counsel, and other key external parties
– Attend conferences, seminars, meetings, and industry events as a representative of Yuhan USA
– Act as a liaison between external partners and internal R&D team; facilitate meetings in regards to product development, R&D collaboration, and other issues
– Perform research and analysis for focused therapeutic areas; report to the management and R&D department

Qualifications:
1. Required
– MS in Life Sciences, Pharmacy, Biological areas, Business or related discipline
– Relevant biotech or pharmaceutical industry experience

2. Preferred
– MBA, Ph.D. or other advanced degree
– Experiences in drug research, development, and commercialization activities

3. Others
– Excellent interpersonal, networking and communication skills
– Fluent in both English and Korean preferred

More To Explore

RYBREVANT® plus LAZCLUZE™ by Johnson & Johnson got approved by the U.S. FDA as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. LAZCLUZE™ is anti-cancer drug developed by Yuhan Corporation licensed out to Janssen Biotech in 2018.  

Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) for the first-line treatment of adult patients